Novo Nordisk A/S

NYSE: NVO · Real-Time Price · USD
52.32
1.37 (2.69%)
At close: Aug 15, 2025, 3:10 PM

Novo Nordisk A/S Income Statement

Financials in DKK. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
290.4B 232.26B 176.95B 140.8B
Cost of Revenue
44.52B 35.77B 28.45B 23.66B
Gross Profit
245.88B 196.5B 148.51B 117.14B
Operating Income
128.34B 102.57B 74.81B 58.64B
Interest Income
1.84B 1.07B 239M 2.89B
Pretax Income
127.19B 104.67B 69.06B 59.08B
Net Income
100.99B 83.68B 55.52B 47.76B
Selling & General & Admin
67.38B 61.6B 50.68B 41.06B
Research & Development
48.06B 32.44B 24.05B 17.77B
Other Expenses
2.1B -119M -1.03B -332M
Operating Expenses
117.54B 93.92B 73.7B 58.5B
Interest Expense
1.64B 739M 378M 2.45B
Selling & Marketing Expenses
62.1B 56.74B 46.22B 37.01B
Cost & Expenses
162.06B 129.69B 102.14B 82.16B
Income Tax Expense
26.2B 20.99B 13.54B 11.32B
Shares Outstanding (Basic)
4.45B 4.48B 4.53B 4.59B
Shares Outstanding (Diluted)
4.46B 4.49B 4.54B 4.61B
EPS (Basic)
22.67 9.34 12.26 10.40
EPS (Diluted)
22.63 9.31 12.22 10.37
EBITDA
137.38B 113.33B 76.41B 64.83B
EBIT
128.83B 105.22B 69.81B 59.52B
Depreciation & Amortization
8.54B 9.41B 6.6B 5.31B